Epidemiology and complications of late-onset sepsis: an Italian area-based study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 16 05 2019
accepted: 03 11 2019
entrez: 23 11 2019
pubmed: 23 11 2019
medline: 21 3 2020
Statut: epublish

Résumé

Most studies regarding late-onset sepsis (LOS) address selected populations (i.e., neonates with low birth weight or extremely preterm neonates). Studying all age groups is more suitable to assess the burden of single pathogens and their clinical relevance. This is a retrospective regional study involving paediatric departments and NICUs in Emilia-Romagna (Italy). Regional laboratory databases were searched from 2009 to 2012. Records of infants (aged 4 to 90 days) with a positive blood or cerebrospinal fluid (CSF) culture were retrospectively reviewed and analysed according to acquisition mode (whether hospital- or community-acquired). During the study period, there were 146,682 live births (LBs), with 296 patients experiencing 331 episodes of LOS (incidence rate: 2.3/1000 LBs). Brain lesions upon discharge from the hospital were found in 12.3% (40/296) of cases, with death occurring in 7.1% (23/296; 0.14/1000 LBs). With respect to full-term neonates, extremely preterm or extremely low birth weight neonates had very high risk of LOS and related mortality (> 100- and > 800-fold higher respectively). Hospital-acquired LOS (n = 209) was significantly associated with very low birth weight, extremely preterm birth, pneumonia, mechanical ventilation, and death (p< 0.01). At multivariate logistic regression analysis, catecholamine support (OR = 3.2), central venous line before LOS (OR = 14.9), and meningitis (OR = 44.7) were associated with brain lesions or death in hospital-acquired LOS (area under the ROC curve 0.81, H-L p = 0.41). Commonly identified pathogens included coagulase-negative staphylococci (CoNS n = 71, 21.4%), Escherichia coli (n = 50, 15.1%), Staphylococcus aureus (n = 41, 12.4%) and Enterobacteriaceae (n = 41, 12.4%). Group B streptococcus was the predominant cause of meningitis (16 of 38 cases, 42%). Most pathogens were sensitive to first line antibiotics. This study provides the first Italian data regarding late-onset sepsis (LOS) in all gestational age groups. Compared to full-term neonates, very high rates of LOS and mortality occurred in neonates with a lower birth weight and gestational age. Group B streptococcus was the leading cause of meningitis. Excluding CoNS, the predominant pathogens were Escherichia coli and Staphylococcus aureus. Neonates with hospital-acquired LOS had a worse outcome. Antibiotic associations, recommended for empirical treatment of hospital- or community-acquired LOS, were adequate.

Sections du résumé

BACKGROUND
Most studies regarding late-onset sepsis (LOS) address selected populations (i.e., neonates with low birth weight or extremely preterm neonates). Studying all age groups is more suitable to assess the burden of single pathogens and their clinical relevance.
METHODS
This is a retrospective regional study involving paediatric departments and NICUs in Emilia-Romagna (Italy). Regional laboratory databases were searched from 2009 to 2012. Records of infants (aged 4 to 90 days) with a positive blood or cerebrospinal fluid (CSF) culture were retrospectively reviewed and analysed according to acquisition mode (whether hospital- or community-acquired).
RESULTS
During the study period, there were 146,682 live births (LBs), with 296 patients experiencing 331 episodes of LOS (incidence rate: 2.3/1000 LBs). Brain lesions upon discharge from the hospital were found in 12.3% (40/296) of cases, with death occurring in 7.1% (23/296; 0.14/1000 LBs). With respect to full-term neonates, extremely preterm or extremely low birth weight neonates had very high risk of LOS and related mortality (> 100- and > 800-fold higher respectively). Hospital-acquired LOS (n = 209) was significantly associated with very low birth weight, extremely preterm birth, pneumonia, mechanical ventilation, and death (p< 0.01). At multivariate logistic regression analysis, catecholamine support (OR = 3.2), central venous line before LOS (OR = 14.9), and meningitis (OR = 44.7) were associated with brain lesions or death in hospital-acquired LOS (area under the ROC curve 0.81, H-L p = 0.41). Commonly identified pathogens included coagulase-negative staphylococci (CoNS n = 71, 21.4%), Escherichia coli (n = 50, 15.1%), Staphylococcus aureus (n = 41, 12.4%) and Enterobacteriaceae (n = 41, 12.4%). Group B streptococcus was the predominant cause of meningitis (16 of 38 cases, 42%). Most pathogens were sensitive to first line antibiotics.
CONCLUSIONS
This study provides the first Italian data regarding late-onset sepsis (LOS) in all gestational age groups. Compared to full-term neonates, very high rates of LOS and mortality occurred in neonates with a lower birth weight and gestational age. Group B streptococcus was the leading cause of meningitis. Excluding CoNS, the predominant pathogens were Escherichia coli and Staphylococcus aureus. Neonates with hospital-acquired LOS had a worse outcome. Antibiotic associations, recommended for empirical treatment of hospital- or community-acquired LOS, were adequate.

Identifiants

pubmed: 31756213
doi: 10.1371/journal.pone.0225407
pii: PONE-D-19-13900
pmc: PMC6874360
doi:

Substances chimiques

Catecholamines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0225407

Déclaration de conflit d'intérêts

This is my amended Competing Interests Statement: Professor Alberto Berardi has received fees (in 2018) from a commercial funder (GSK) for a phone interview. This does not alter adherence to PLOS ONE policies on sharing data and materials. I declare that there are no competing interest concerning the content of this manuscript. I have no further relevant declarations relating to employment, consultancy, patents, products in development, marketed products.

Références

Arch Dis Child Fetal Neonatal Ed. 2011 Jan;96(1):F9-F14
pubmed: 20876594
Arch Dis Child Fetal Neonatal Ed. 2019 May;104(3):F293-F297
pubmed: 29954881
Pediatrics. 2004 Aug;114(2):348-55
pubmed: 15286215
J Med Screen. 2011;18(2):60-4
pubmed: 21852697
MMWR Recomm Rep. 2002 Aug 16;51(RR-11):1-22
pubmed: 12211284
Early Hum Dev. 2012 May;88 Suppl 2:S69-74
pubmed: 22633519
J Pediatr. 2018 Oct;201:106-114.e4
pubmed: 30054165
J Microbiol Immunol Infect. 2004 Oct;37(5):301-6
pubmed: 15497012
J Pediatr. 2015 May;166(5):1193-9
pubmed: 25919728
Pediatr Infect Dis J. 2014 Jan;33(1):e7-e13
pubmed: 23899966
Arch Dis Child Fetal Neonatal Ed. 2015 May;100(3):F257-63
pubmed: 25425653
Pediatrics. 2002 Aug;110(2 Pt 1):285-91
pubmed: 12165580
Arch Dis Child Fetal Neonatal Ed. 2018 Nov;103(6):F547-F553
pubmed: 29208666
Clin Perinatol. 2015 Mar;42(1):29-45, vii-viii
pubmed: 25677995
Pediatr Infect Dis J. 2017 Aug;36(8):774-779
pubmed: 28709162
Am J Infect Control. 2007 Apr;35(3):177-82
pubmed: 17433941
Am J Perinatol. 2015 Jun;32(7):675-82
pubmed: 25486288
Eur J Pediatr. 2012 Apr;171(4):681-7
pubmed: 22134805
J Pediatr. 2013 Jun;162(6):1120-4, 1124.e1
pubmed: 23324523
Pediatrics. 2011 Aug;128(2):e348-57
pubmed: 21768312
Pediatrics. 2005 Sep;116(3):595-602
pubmed: 16140698
J Matern Fetal Neonatal Med. 2017 Jul;30(14):1739-1744
pubmed: 27593156
JAMA. 2004 Nov 17;292(19):2357-65
pubmed: 15547163
Pediatr Infect Dis J. 2000 Jan;19(1):56-65
pubmed: 10643852
MMWR Recomm Rep. 2010 Nov 19;59(RR-10):1-36
pubmed: 21088663
Expert Rev Anti Infect Ther. 2015;13(11):1387-99
pubmed: 26295167
Pediatr Infect Dis J. 2013 Jul;32(7):e265-71
pubmed: 23385951
J Matern Fetal Neonatal Med. 2016 Oct;29(19):3126-31
pubmed: 26515917
Pediatr Infect Dis J. 2017 Sep;36(9):883-888
pubmed: 28178107
Virulence. 2014 Jan 1;5(1):170-8
pubmed: 24185532

Auteurs

Alberto Berardi (A)

Unità Operativa di Terapia Intensiva Neonatale, Dipartimento Integrato Materno-Infantile, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy.

Francesca Sforza (F)

Medico in formazione, Scuola di Specializzazione in Pediatria, Università degli Studi di Modena e Reggio, Modena, Italy.

Lorenza Baroni (L)

Terapia Intensiva Neonatale, Dipartimento Ostetrico e Pediatrico, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

Caterina Spada (C)

Medico in formazione, Scuola di Specializzazione in Pediatria, Università degli Studi di Modena e Reggio, Modena, Italy.

Simone Ambretti (S)

Unità Operativa di Microbiologia, Azienda Ospedaliero-Universitaria S. Orsola-Malpighi, Bologna, Italy.

Giacomo Biasucci (G)

Unità Operativa di Pediatria, Ospedale G da Saliceto, Piacenza, Italy.

Serenella Bolognesi (S)

Unità Operativa di Terapia Intensiva Neonatale, Ospedale Infermi, Rimini, Italy.

Mariagrazia Capretti (M)

Unità Operativa di Neonatologia, Dipartimento Del Bambino, Della Donna E Delle Malattie Urologiche, Azienda Ospedaliero-Universitaria Sant'Orsola-Malpighi, Bologna, Italy.

Edoardo Carretto (E)

Laboratorio di Microbiologia, Dipartimento Interaziendale di Diagnostica per Immagini e Medicina di Laboratorio, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

Matilde Ciccia (M)

Unità Operativa di Terapia Intensiva Neonatale, Dipartimento Materno Infantile, Ospedale Maggiore, Bologna, Italy.

Marcello Lanari (M)

Unità Operativa di Pediatria, Dipartimento Del Bambino, Della Donna E Delle Malattie Urologiche, Azienda Ospedaliero-Universitaria Sant'Orsola-Malpighi, Bologna, Italy.

Maria Federica Pedna (MF)

Unità Operativa di Microbiologia, Laboratorio Unico Ausl della Romagna, Pievesestina Cesena, Italy.

Vittoria Rizzo (V)

Unità Operativa di Terapia Intensiva Neonatale e Pediatrica, Ospedale Civile M. Bufalini, Cesena, Italy.

Claudia Venturelli (C)

Struttura Complessa di Microbiologia e Virologia, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy.

Crisoula Tzialla (C)

Neonatologia, Patologia Neonatale e Terapia Intensiva Neonatale, Fondazione IRCCS Policlinico "San Matteo", Pavia, Italy.

Laura Lucaccioni (L)

Unità Operativa di Terapia Intensiva Neonatale, Dipartimento Integrato Materno-Infantile, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy.

Maria Letizia Bacchi Reggiani (MLB)

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Azienda Ospedaliero-Universitaria S. Orsola-Malpighi-Università di Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH